The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
Open accessAbstract
BACKGROUND: Patients with congestive heart failure have a high mortality rate and are also hospitalized frequently. We studied the effect of an angiotensin-converting-enzyme inhibitor, enalapril, on mortality and hospitalization in patients with chronic heart failure and ejection fractions less than or equal to 0.35. METHODS: Patients receiving conventional treatment for heart failure were randomly assigned to receive either placebo (n = 1284) or enalapril (n = 1285) at doses of 2.5 to 20 mg per day in a double-bind trial. Approximately 90 percent of the patients were in New York Heart Association functional classes II and III. The follow-up averaged 41.4 months. RESULTS: There were 510 deaths in the placebo group (39.7 percent), as compared with 452 in the enalapril group (35.2 percent) (reduction in risk, 16 percent; 95 percent confidence interval, 5 to 26 percent; P = 0.0036). Although reductions in mortality were observed in several categories of cardiac deaths, the largest reduction occurred among the deaths attributed to progressive heart failure (251 in the placebo group vs. 209 in the enalapril group; reduction in risk, 22 percent; 95 percent confidence interval, 6 to 35 percent). There was little apparent effect of treatment on deaths classified as due to arrhythmia without pump failure. Fewer patients died or were hospitalized for worsening heart failure (736 in the placebo group and 613 in the enalapril group; risk reduction, 26 percent; 95 percent confidence interval, 18 to 34 percent; P less than 0.0001). CONCLUSIONS: The addition of enalapril to conventional therapy significantly reduced mortality and hospitalizations for heart failure in patients with chronic congestive heart failure and reduced ejection fractions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The coexistence of type 2 diabetes mellitus (T2DM) and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent (30-40% of patients)”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [36]
In the citing paper
“In clinical trials of chronic HF patients, the prevalence of T2DM was around 30%, irrespective of HF phenotype (i.e.HFrEF and HFpEF) (Table 3).31 -48”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [36]
In the citing paper
“The highest prevalence of T2DM was seen in trials of acute HF (around 40%).”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Recommendations for Quantitation of the Left Ventricle by Two-Dimensional Echocardiography
Schiller, N. B., Shah, P. M., Crawford, M., DeMaria, A. N., Devereux, R. B., Feigenbaum, H., Gutgesell, H. P., Reichek, N., Sahn, D. J., Schnittger, I., et al. (1989) · Journal of the American Society of Echocardiography · doi:10.1016/s0894-7317(89)80014-8 · Cited by 8,110
Effects of Enalapril on Mortality in Severe Congestive Heart Failure
The Consensus Trial Study Group* (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162301 · Cited by 5,109
The natural history of congestive heart failure: the Framingham study
McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971) · New England Journal of Medicine · doi:10.1056/nejm197112232852601 · Cited by 3,448
Effect of Vasodilator Therapy on Mortality in Chronic Congestive Heart Failure
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606123142404 · Cited by 2,400
Discrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Discrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310
Francis, G. S., Benedict, C. R., Johnstone, D. E., Kirlin, P. C., Nicklas, J. M., Liang, C., Kubo, S. H., Rudin-Toretsky, E., & Yusuf, S. (1990) · Circulation · doi:10.1161/01.cir.82.5.1724 · Cited by 1,386
Research works printed but not linked: 1
- Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
Cited by
Sorted by citations
Items 1,001–1,027 of 1,027
Murphy, D. P., Drawz, P. E., & Foley, R. N. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018100971 · Cited by 106
Ayanian, J. Z., Weissman, J. S., Chasan-Taber, S., & Epstein, A. M. (1998) · Health Affairs · doi:10.1377/hlthaff.17.6.194 · Cited by 106
Bowling, C. B., Sanders, P. W., Allman, R. M., Rogers, W. J., Patel, K., Aban, I. B., Rich, M. W., Pitt, B., White, M., Bakris, G. C., et al. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.12.056 · Cited by 85
Pathophysiologic and therapeutic implicationsof sleep apnea in congestive heart failure
Bradley, T. D., & Floras, J. S. (1996) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(96)80045-5 · Cited by 78
Demers, C. (2005) · JAMA · doi:10.1001/jama.294.14.1794 · Cited by 78
Underutilisation of ACE inhibitors in patients with congestive heart failure.
Bungard, T. J., McAlister, F. A., Johnson, J. A., & Tsuyuki, R. T. (2001) · Drugs · doi:10.2165/00003495-200161140-00002 · Cited by 73
Calcium channel blockers in heart failure
Elkayam, U. (1998) · Cardiology · doi:10.1159/000047278 · Cited by 69
Basu, S., Wagner, R. G., Sewpaul, R., Reddy, P., & Davies, J. (2019) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30450-9 · Cited by 69
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Schaufelberger, M., Andersson, G., Eriksson, B. O., Grimby, G., Held, P., & Swedberg, K. (1996) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a014751 · Cited by 55
OXIDATIVE STRESS AND THE PATHOGENESIS OF HEART FAILURE
Ball, A. M. M., & Sole, M. J. (1998) · Cardiology Clinics · doi:10.1016/s0733-8651(05)70043-6 · Cited by 53
Byrd, J. B., Shreevatsa, A., Putlur, P., Foretia, D., McAlexander, L., Sinha, T., Does, M. D., & Brown, N. J. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.04.012 · Cited by 52
Sanam, K., Bhatia, V., Bajaj, N. S., Gaba, S., Morgan, C. J., Fonarow, G. C., Butler, J., Deedwania, P., Prabhu, S. D., Wu, W.-C., et al. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.05.008 · Cited by 50
Goel, S. S., Kleiman, N. S., Zoghbi, W. A., Reardon, M. J., & Kapadia, S. R. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.016911 · Cited by 43
Dewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure · doi:10.1002/ejhf.1867 · Cited by 41
Krombach, R. (1998) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00050-9 · Cited by 40
Contemporary Drug Development in Heart Failure: Call for Hemodynamically Neutral Therapies
Vaduganathan, M., Butler, J., Pitt, B., & Gheorghiade, M. (2015) · Circulation: Heart Failure · doi:10.1161/circheartfailure.115.002271 · Cited by 38
Witte, K. K., Drozd, M., Walker, A. M. N., Patel, P. A., Kearney, J. C., Chapman, S., Sapsford, R. J., Gierula, J., Paton, M. F., Lowry, J., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1406 · Cited by 36
Screening for Asymptomatic Left Ventricular Dysfunction Using B‐Type Natriuretic Peptide
McDonagh, T. A., McDonald, K., & Maisel, A. S. (2008) · Congestive Heart Failure · doi:10.1111/j.1751-7133.2008.tb00002.x · Cited by 35
Avins, A. L., Pressman, A., Ackerson, L., Rudd, P., Neuhaus, J., & Vittinghoff, E. (2010) · Journal of General Internal Medicine · doi:10.1007/s11606-010-1477-8 · Cited by 33
Dilated Cardiomyopathy: From Genetics to Clinical Management
(2019) · doi:10.1007/978-3-030-13864-6 · Cited by 32
Kane, J. A., Kim, J. K., Haidry, S. A., Salciccioli, L., & Lazar, J. (2017) · Cardiology · doi:10.1159/000457946 · Cited by 30
Effect of enalapril maleate on cerebral blood flow in patients with chronic heart failure.
Kamishirado, H., Inoue, T., Fujito, T., Kase, M., Shimizu, M., Sakai, Y., Takayanagi, K., Morooka, S., Natsui, S., & Kamishirado, H. (1997) · Angiology · doi:10.1177/000331979704800806 · Cited by 27
Observational cohort study of the safety of digoxin use in women with heart failure
Flory, J. H., Ky, B., Haynes, K., M Brunelli, S., Munson, J., Rowan, C., Strom, B. L., & Hennessy, S. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-000888 · Cited by 27
Li, M., Ma, W., Fan, F., Yi, T., Qiu, L., Wang, Z., Weng, H., Zhang, Y., Li, J., & Huo, Y. (2023) · Journal of Cardiology · doi:10.1016/j.jjcc.2023.01.010 · Cited by 22
The role of inflammation in the pathogenesis of heart failure
Lisman, K. A., Stetson, S. J., Koerner, M. M., Farmer, J. A., & Torre-Amione, G. (2002) · Current Cardiology Reports · doi:10.1007/s11886-002-0051-3 · Cited by 18
Siddiqui, W. J., Aggarwal, S., Rafique, M., Singh, S., Kutalek, S., & Eisen, H. J. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9671-6 · Cited by 16
Metadata
- Authors
- The SOLVD Investigators*
- Corresponding author
- The SOLVD Investigators*
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 1991-08
- Volume
- 325
- Issue
- 5
- Pages
- 293-302
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2585382523
- Cited by
- 8,029
- References
- 15
- Citations by year
- 2026: 78 · 2025: 89 · 2024: 117 · 2023: 152 · 2022: 174 · 2021: 167 · 2020: 182 · 2019: 174 · 2018: 174 · 2017: 187 · 2016: 211 · 2015: 208 · 2014: 165 · 2013: 168 · 2012: 231
- FWCI
- 170.62
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- enalapril, ACE inhibitors, congestive heart failure, reduced left ventricular ejection fraction, mortality, hospitalization, heart failure progression, cardiac arrhythmias, NYHA functional class
- MeSH terms
- Blood Pressure, Cause of Death, Chronic Disease, Double-Blind Method, Electrolytes, Enalapril, Female, Follow-Up Studies, Heart Failure, Hospitalization, Humans, Kidney, Male, Middle Aged, Patient Compliance, Stroke Volume, Survival Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
